PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.
PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.